Sort by
Refine Your Search
-
neurobiology, RNA biology, and evolution. We are especially interested in understanding: How does post-transcriptional control shape neural cell fate and disease? We have discovered canonical and non-canonical
-
, and apply Crainbow mouse models that express multiple HER2 isoforms — wild-type (WT), D16, and p95 which are essential reagents for the laboratory’s DoD funded program. Minimum Requirements: Ph.D
-
therapeutic resistance in lung and head and neck cancers using integrated genetic, molecular, and computational approaches. We are particularly interested in discovering new therapeutic vulnerabilities and
-
breast cancer research program focused on mechanisms of tumor progression, therapeutic resistance, and tumor-immune interactions. The successful candidate will lead experimental projects using breast
-
behavioral data will be viewed favorably. • Applicants’ ideas about how their research program could contribute to research in the Lab will also be a plus. Position Details: This position will be in-person
-
these help communicate their ideas. For questions pertaining to this position, please send an email to [email protected] and someone from our leadership team will respond. General Information
-
seven days after the job posts to Academic Jobs Online and continue until the position is filled. Start date is August 1st, 2026. Applicants should upload the following to Academic Jobs Online: a
-
foundation for an independent research trajectory. REGAL is a multidisciplinary research program integrating social epidemiology, molecular epidemiology, and global health to investigate the drivers of cancer
-
Associate to join a collaborative research program investigating the endocrine-disrupting potential of plastic additives. This position offers a unique opportunity to conduct rigorous pharmacological and
-
growing portfolio of trauma, critical care, nutrition, ethics, and clinical informatics research. This position will coordinate complex, multi-component studies that include prospective patient enrollment